Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
about
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settingsChanges in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDSNevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with AtazanavirEvolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatmentNo impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trialInhibitors of virus replication: recent developments and prospects.Atazanavir: a review of its use in the management of HIV-1 infection.Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infectionThe metabolic effects of lopinavir/ritonavir in HIV-negative menLong-term treatment of patients with HIV-1: the role of atazanavirOnce-daily therapy: less is more.Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapyInitial therapy for human immunodeficiency virus: broadening the options.Atazanavir: new option for treatment of HIV infection.Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE studyPharmacologic perspectives for once-daily antiretroviral therapy.The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.Therapy of HIV infection.Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.Atazanavir for the treatment of human immunodeficiency virus infection.Antiretroviral drugs: critical issues and recent advancesCoronary heart disease risk, dyslipidemia, and management in HIV-infected persons.Atazanavir: the advent of a new generation of more convenient protease inhibitors.Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.HIV-associated lipodystrophy syndrome: A review of clinical aspects.Nelfinavir: a review of its use in the management of HIV infection.Strategies for management and treatment of dyslipidemia in HIV/AIDS.Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.New antiretroviral drugs in clinical use.Association between Medication Adherence Outcomes and Adverse Drug Reactions to Highly Active Antiretroviral Therapy in Indian Human Immunodeficiency Virus-Positive Patients.Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Atazanavir: simplicity and convenience in different scenarios.Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).Role of atazanavir in the treatment of HIV infectionAtazanavir: its role in HIV treatment
P2860
Q21144607-F975548E-D90A-4CAD-8D89-FDA5DFAC39C6Q24792952-551F808F-5A77-406A-B130-7F24E9F57855Q24802369-72C619F1-C213-4667-BAA4-0639397C23DFQ27645052-5D3EBD23-1F07-4FEF-892F-C8E3B47A5087Q28471623-07A64FD3-149C-4915-9644-432A346DF8BCQ34056642-6F21BC52-1066-43BD-8B92-46445A1310DDQ34375688-3BBBDFD1-4FDB-4A84-A1D8-7FCDEB60195AQ34984899-5163B983-41C1-4018-9B29-25CDE64ED234Q35127808-8C624C77-CF98-46BB-A9E5-387B13A89D39Q35194394-96538741-EDE1-454E-ABE8-33AE0DA97623Q35557219-696A4800-615E-48DB-9CE9-414C8DEBCCB8Q35583692-384BCC88-39CC-47BC-B142-66C6095FB2DFQ35689246-92985FC0-D34F-41CF-9FEE-C89918A52FC5Q35759609-4AB007C8-FF24-41A9-B4C2-DA62C77889B2Q35779915-19A50E8B-1D45-40A5-AA09-4ACB7B07B426Q35908862-B8A37856-FC7C-4789-A123-6224E4971A6FQ35915916-51288EE2-56DE-4CBB-B833-540BEBA022F2Q35946036-0F86A893-9862-4CAA-861F-4EBF04884D0CQ35967419-561B3B85-75E8-4BFD-AD35-3417697A5B26Q35968731-D76AFDE1-69AD-490E-8F32-A080FC7D6AEAQ35976835-214E543B-81A9-49DE-9F55-3F0B741C3829Q36020992-AB8F102B-85BA-49B8-8E28-66F3FE2EA306Q36025409-A8EAB351-4CB4-4888-B247-E991557FCC7FQ36070100-B40F05CE-9E7B-46D6-905C-EA1A09F7616BQ36094771-D09BCCD2-6CDD-4B84-8FE3-DF65EAE4CCD5Q36171069-CA631C92-F46A-443A-8021-18AFD3116E01Q36286228-22AAAD3A-F63D-437E-9E12-5038527DCE30Q36336563-C237A45A-49FE-4245-B72B-D18396D3D828Q36425083-6DEE3552-E43B-4B82-B4D3-D9E655479687Q36525658-ACAA2E4F-F404-4AB7-9A1C-F4B3FCBD30ECQ36612492-B1F4F832-69B5-42CA-8574-8D10115897FAQ36628549-7AEB5B67-521B-4116-B46F-4E34F9094302Q36634838-54BD9E94-3EB0-4E6A-A7B2-480CA8CA9314Q36653838-456A42D8-BBE1-425E-A99F-84254D70E720Q36723853-A309105C-9E62-4C03-A93F-8B2F16F88F7CQ36765802-FEAEEF63-B980-4B8F-9338-5B2790C685B6Q36818306-78629E52-0029-499F-82CE-4F71BF1FE883Q36901492-E09D2388-FB4E-4EC3-AAC0-0E7FC1D8B593Q37230298-8F1B7452-8775-45B0-878D-A6F7FAA4B2A3Q37249418-515212F4-D674-4742-8D0D-703BED1A564C
P2860
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Results of a phase 2 clinical ...... antiretroviral-naive subjects.
@en
Results of a phase 2 clinical ...... antiretroviral-naive subjects.
@nl
type
label
Results of a phase 2 clinical ...... antiretroviral-naive subjects.
@en
Results of a phase 2 clinical ...... antiretroviral-naive subjects.
@nl
prefLabel
Results of a phase 2 clinical ...... antiretroviral-naive subjects.
@en
Results of a phase 2 clinical ...... antiretroviral-naive subjects.
@nl
P2093
P1476
Results of a phase 2 clinical ...... antiretroviral-naive subjects.
@en
P2093
AI424-007 Clinical Trial Group
Alexandra Thiry
Kathleen Squires
Peter Piliero
Steven Schnittman
P356
10.1097/00126334-200301010-00004
P407
P577
2003-01-01T00:00:00Z